World Journal of Pharmaceutical Science and Research

www.wjpsronline.com

Review Article

ISSN: 2583-6579
SJIF Impact Factor: 6.916
Year - 2026
Volume: 5; Issue: 8
Page: 808-819

A COMPREHENSIVE REVIEW ON PHARMACEUTICAL POLYMERS AND THEIR ROLE IN THE DEVELOPMENT OF CONTROLLED RELEASE DRUG DELIVERY SYSTEMS

Dr. Vijay Bahadur Maurya*, Dr. Rajeev Kumar

Institute of Pharmacy, V. B. S. Purvanchal University, Jaunpur, UP.

Article Received: 25 June 2026 | | ***Article Revised: 16 July 2026*** | | ***Article Accepted: 06 August 2026***

***Corresponding Author: Dr. Vijay Bahadur Maurya**
Institute of Pharmacy, V. B. S. Purvanchal University, Jaunpur, UP.
DOI: https://doi.org/10.5281/zenodo.21949621

How to cite this Article: Dr. Vijay Bahadur Maurya, Dr. Rajeev Kumar (2026) A COMPREHENSIVE REVIEW ON PHARMACEUTICAL POLYMERS AND THEIR ROLE IN THE DEVELOPMENT OF CONTROLLED RELEASE DRUG DELIVERY SYSTEMS. World Journal of Pharmaceutical Science and Research, 5(8), 808-819.

ABSTRACT

Polymers are essential components in the development of controlled release drug delivery systems because of their unique physicochemical, biodegradable, and biocompatible properties. They enhance drug stability, solubility, bioavailability, and therapeutic efficacy while minimizing dosing frequency and adverse effects. This review discusses the classification of polymers based on their mechanism of action, biodegradability, release kinetics, processing methods, and pharmaceutical applications. Key polymer properties, including molecular weight, hydrophobicity, crosslinking density, thermal behavior, chemical stability, mechanical strength, and pH responsiveness, are highlighted for their influence on drug release profiles. The review also emphasizes the role of natural and synthetic polymers in designing advanced dosage forms for oral, transdermal, injectable, ophthalmic, nasal, pulmonary, and implantable drug delivery systems. Recent advances in polymer technology have enabled the development of targeted, site- specific, and stimuli-responsive drug delivery platforms. Overall, polymers remain indispensable materials for improving formulation performance, patient compliance, and the future of personalized pharmaceutical therapies.

KEYWORDS: Polymers, Biodegradable Polymers, Controlled Drug Release, Polymeric Drug Carriers.

INTRODUCTION

Polymers have become indispensable in the pharmaceutical industry due to their versatile properties and wide-ranging applications. These large molecules, composed of repeating structural units called monomers, offer a plethora of advantages in drug delivery systems, formulation development, and biomedical applications. From enhancing drug solubility to controlling drug release, polymers play a pivotal role in modern pharmaceutical science.[1]

Polymers are macromolecules composed of repeating units called monomers. These monomers can vary in structure, giving rise to a vast array of polymers with distinct properties. The properties of polymers crucially depend on factors such as molecular weight, polymer chain architecture, and chemical composition. These properties can be tailored to meet specific pharmaceutical requirements, making polymers highly adaptable materials in drug development.[2]

Classification of polymers

Polymers play a crucial role in the formulation of controlled release drug delivery systems, allowing for precise modulation of drug release kinetics and targeting specific sites of action. These polymers can be classified based on their mechanism of action, biodegradability, and release kinetics. Here's a classification of polymers commonly used in the formulation of controlled release drug delivery systems:

A. Based on Mechanism of Action

1. **Diffusion-Controlled Polymers:** These polymers regulate drug release through diffusion of the drug molecules through the polymer matrix. Examples include hydrophilic polymers like hydroxypropyl methylcellulose (HPMC), hydroxyethyl cellulose (HEC), and hydroxypropyl cellulose (HPC), as well as hydrophobic polymers like ethyl cellulose and polyethylene oxide (PEO).[3]
2. **Swelling-Controlled Polymers:** These polymers swell upon exposure to aqueous fluids, creating a gel-like matrix that controls drug release. Examples include sodium carboxymethyl cellulose (NaCMC), poly(acrylic acid) (PAA), and polyvinyl alcohol (PVA).[4]
3. **Erosion-Controlled Polymers:** In erosion-controlled systems, the polymer matrix degrades or erodes over time, releasing the encapsulated drug. Biodegradable polymers such as poly(lactic-co-glycolic acid) (PLGA), polylactic acid (PLA), and poly(caprolactone) (PCL) are commonly used for this purpose.[5]

B. Based on Biodegradability

1. **Biodegradable Polymers:** These polymers degrade into biocompatible byproducts over time, reducing the risk of long-term accumulation and potential toxicity. Examples include PLGA, PLA, PCL, and polyhydroxyalkanoates (PHAs).[6]
2. **Non-biodegradable Polymers:** While non-biodegradable polymers do not degrade in biological environments, they can still be used in controlled release formulations. Examples include ethyl cellulose, polyvinyl chloride (PVC), and silicone elastomers.[7]

C. Based on Release Kinetics

1. **Zero-Order Release Polymers:** These polymers provide a constant rate of drug release over time, independent of drug concentration. Examples include non-porous polymeric membranes and hydrophilic polymers like HPMC.[8]
2. **First-Order Release Polymers:** In first-order release systems, drug release occurs exponentially over time, typically due to diffusion or erosion processes. Examples include PLGA and ethyl cellulose.
3. **Non-linear Release Polymers:** Some polymers exhibit non-linear release kinetics, where drug release is influenced by factors such as pH, temperature, or enzymatic activity. These polymers can be tailored to achieve specific release profiles for different therapeutic applications.[9]

D. Based on Specific Applications

1. **Mucoadhesive Polymers:** Polymers designed to adhere to mucosal surfaces, prolonging drug residence time and enhancing local drug delivery. Examples include chitosan, carbopol, and alginate.[10]
2. **pH-Sensitive Polymers:** Polymers that respond to changes in pH, allowing for targeted drug release in specific regions of the gastrointestinal tract. Examples include Eudragit® polymers and cellulose acetate phthalate (CAP).[11]

E. Based on Processing Method

1. **Microporous Polymers:** Polymers with interconnected micropores or nanopores, facilitating sustained drug release through diffusion or desorption processes. Examples include porous silicon, polymeric foams, and mesoporous silica.[12]
2. **Sprayable Polymers:** Polymers formulated into sprayable formulations for localized or systemic drug delivery, enabling convenient administration and targeted release. Examples include polymeric sprays for nasal, pulmonary, or transdermal delivery.[13]

F. Based on Mechanism of Drug Encapsulation:

1. **Encapsulating Polymers:** Polymers that encapsulate drug molecules within their matrix or cavities, providing protection and controlled release. Examples include cyclodextrins, liposomes, and polymer-drug conjugates.[14]
2. **Matrix Polymers:** Polymers that entrap drug molecules within their structure, allowing for sustained or controlled release over time. Examples include hydrogels, microspheres, and nanoparticles.[15]

Properties of polymer

Polymer properties play a crucial role in the development of controlled release formulations, which are designed to release active ingredients at a predetermined rate over an extended period. These formulations are widely used in pharmaceuticals, agriculture, cosmetics, and other industries. Here's a discussion on the key properties of polymers relevant to controlled release formulations:

Biodegradability: Biodegradable polymers undergo degradation into non-toxic byproducts, which is advantageous for controlled release formulations, especially in biomedical applications. Polymers like polylactic acid (PLA), polyglycolic acid (PGA), and their copolymers (PLGA) are commonly used due to their biodegradability.

Hydrophobicity/Hydrophilicity: Polymer hydrophobicity or hydrophilicity influences the release profile of active ingredients. Hydrophobic polymers tend to release drugs slowly, as they repel water, whereas hydrophilic polymers absorb water and release drugs more rapidly. By blending hydrophilic and hydrophobic polymers, one can tailor the release kinetics to achieve desired profiles.[16]

Molecular Weight: Polymer molecular weight affects the diffusion rate of drugs through the polymer matrix. Higher molecular weight polymers typically result in slower drug release due to increased tortuosity within the polymer matrix, hindering drug diffusion.

Crosslinking Density: Crosslinking density impacts the porosity and mechanical strength of the polymer matrix, thereby influencing drug diffusion and release rates. Higher crosslinking densities generally lead to slower release rates as they reduce the permeability of the polymer matrix.[17]

Thermal Properties: Thermal properties such as glass transition temperature (Tg) and melting point influence polymer stability and drug release behavior. Polymers with Tg above ambient temperature tend to be more rigid and exhibit slower drug release rates, while those with Tg below ambient temperature are more flexible and may release drugs more rapidly.[18]

Chemical Stability: Polymers must be chemically stable under physiological conditions to prevent degradation or adverse reactions with the encapsulated drug. Stability against hydrolysis, oxidation, and enzymatic degradation is particularly important for long-term controlled release applications.

Compatibility with Active Ingredients: Polymers should be compatible with the active ingredients to ensure stability and efficacy. Incompatibility can lead to drug degradation, altered release kinetics, or even loss of therapeutic activity.

Controlled Release Mechanisms: Polymers can facilitate controlled release through various mechanisms, including diffusion, erosion, swelling, and chemical reactions. The choice of polymer and formulation design determines the predominant release mechanism.

Ease of Processing: Processability is essential for manufacturing-controlled release formulations on an industrial scale. Polymers should be easily processable into desired shapes (e.g., films, microspheres, implants) using common techniques such as extrusion, compression, or solvent casting.

Regulatory Approval and Safety: Polymers used in controlled release formulations must comply with regulatory requirements for safety, biocompatibility, and biodegradability, particularly in pharmaceutical applications. Understanding the regulatory landscape is crucial for the development and commercialization of controlled release products.

pH Responsiveness: pH-responsive polymers exhibit changes in swelling and dissolution properties in response to variations in pH. This property can be leveraged to design formulations that release drugs selectively in specific pH environments within the body, such as the acidic environment of the stomach or the neutral pH of the intestine.[19]

Surface Area: The surface area of polymer particles or matrices influences the rate of drug release. Higher surface area generally correlates with faster release rates due to increased contact between the polymer and the surrounding medium, facilitating diffusion or erosion processes.

Solubility Parameters: Matching the solubility parameters of polymers with those of the active ingredient can enhance compatibility and promote homogeneous drug distribution within the polymer matrix. This compatibility often leads to more predictable and reproducible release kinetics.

Electrical Properties: Some polymers exhibit electrical conductivity or chargeability, which can be exploited for controlled release applications. Electrically controlled release systems, such as iontophoresis or electroporation, use polymers that respond to electrical stimuli to modulate drug release rates.[20]

Mechanical Strength: The mechanical strength of polymers influences the integrity and durability of controlled release formulations, particularly for implants or devices intended for prolonged use. Polymers with adequate mechanical properties can withstand physiological stresses and maintain their functionality over extended periods.

Sterilization Compatibility: Polymers used in pharmaceutical or biomedical applications must be compatible with sterilization methods such as gamma irradiation, ethylene oxide gas, or steam sterilization. Ensuring sterilization compatibility is essential to maintain product safety and efficacy.[21]

Environmental Impact: Consideration of the environmental impact of polymers is becoming increasingly important. Biodegradable and renewable polymers offer eco-friendly alternatives to traditional synthetic polymers derived from fossil fuels, aligning with sustainability objectives in controlled release formulation development.

Cost-effectiveness: The cost of polymers influences the overall economics of controlled release formulations. Balancing performance requirements with cost considerations is essential for achieving commercially viable products, especially in industries with stringent cost constraints such as generic pharmaceuticals or agricultural chemicals.

Advantages of polymer

Polymer-based controlled release formulations offer several advantages over traditional dosage forms, making them a preferred choice in various industries, particularly pharmaceuticals. Here are some of the key advantages:

Tailored Release Kinetics: Polymers provide versatile platforms for designing controlled release formulations with precisely tailored release kinetics. By selecting polymers with specific properties and modifying formulation parameters, release profiles can be customized to match the desired therapeutic requirements, such as sustained, pulsatile, or targeted release.[22]

Enhanced Bioavailability: Controlled release formulations can improve the bioavailability of drugs by maintaining therapeutic concentrations in the bloodstream over an extended period. This sustained release can reduce dosing frequency, minimize fluctuations in plasma drug levels, and enhance patient compliance, particularly for medications requiring frequent administration.

Improved Patient Compliance and Convenience: Extended-release formulations offer the convenience of less frequent dosing, which can improve patient adherence to treatment regimens. This is especially beneficial for chronic conditions requiring long-term therapy, as patients are less likely to miss doses or experience interruptions in treatment.

Reduced Side Effects and Toxicity: Controlled release formulations can mitigate side effects and toxicity associated with rapid drug release by minimizing peak plasma concentrations and reducing fluctuations in drug levels. This controlled delivery profile can improve safety and tolerability, enhancing the overall therapeutic profile of the medication.

Stabilization of Labile Drugs: Polymers can provide a protective environment for labile drugs, such as peptides, proteins, and nucleic acids, shielding them from degradation by enzymes, pH fluctuations, or oxidative processes. This stabilization allows for the formulation of sensitive drugs into controlled release dosage forms while maintaining their integrity and efficacy.

Localized Delivery and Targeting: Polymer-based delivery systems enable localized drug delivery to specific anatomical sites, such as tumors, inflamed tissues, or intraocular compartments. By incorporating targeting ligands or

stimuli-responsive polymers, controlled release formulations can selectively release drugs at the desired site of action, minimizing systemic exposure and off-target effects.[23]

Versatility in Formulation Design: Polymers offer versatility in formulation design, allowing for the development of various dosage forms, including tablets, capsules, films, patches, implants, and microspheres. This flexibility enables formulation scientists to choose the most suitable delivery system based on the drug's physicochemical properties, therapeutic requirements, and patient preferences.

Scale-up and Manufacturing Efficiency: Controlled release formulations based on polymers are often amenable to scale-up and manufacturing processes, facilitating commercial production and ensuring consistent quality and performance. Common manufacturing techniques, such as hot-melt extrusion, spray drying, or solvent casting, can be readily adapted for large-scale production of polymer-based dosage forms.

Protection from First-Pass Metabolism: Certain drugs undergo extensive first-pass metabolism in the liver, resulting in reduced bioavailability when administered orally. Controlled release formulations can prolong drug release and reduce the peak plasma concentration, thereby minimizing first-pass metabolism and enhancing drug absorption.

Flexibility in Release Triggering: Polymers can be engineered to respond to various stimuli, such as pH, temperature, enzymatic activity, or external triggers like magnetic fields or ultrasound. This responsiveness allows for on-demand or triggered release of drugs at specific time points or physiological conditions, enhancing therapeutic efficacy and minimizing systemic exposure.[24]

Combination Therapy: Polymer-based controlled release systems enable the incorporation of multiple drugs with different release kinetics into a single dosage form. This facilitates combination therapy by delivering synergistic or complementary drugs simultaneously, optimizing therapeutic outcomes and simplifying dosing regimens for patients.

Long-Term Therapy: For chronic conditions requiring prolonged treatment, polymer-based controlled release formulations offer sustained drug release over extended periods, reducing the frequency of administration and improving patient compliance. This is particularly beneficial for diseases such as diabetes, hypertension, or HIV/AIDS, where long-term therapy is essential for disease management.

Reduced Variability in Pharmacokinetics: Controlled release formulations help minimize inter- and intra-patient variability in drug pharmacokinetics by maintaining consistent drug release rates and plasma concentrations over time. This reduces the risk of under- or overdosing, improving therapeutic efficacy and safety across patient populations.

Patent Protection and Market Exclusivity: Formulating drugs into controlled release formulations can extend patent protection and market exclusivity for pharmaceutical companies, providing a competitive advantage and prolonging product lifecycle. This incentivizes investment in research and development of innovative drug delivery technologies based on polymers.

Customization for Special Populations: Controlled release formulations can be customized to meet the unique needs of special patient populations, such as pediatric, geriatric, or patients with swallowing difficulties. Modified dosage

forms, such as orally disintegrating tablets or transdermal patches, can improve medication adherence and enhance therapeutic outcomes in these populations.

Minimization of Drug-Waste: Controlled release formulations minimize drug wastage by delivering drugs in a controlled and predictable manner, reducing the need for frequent dosing and excess drug administration. This is particularly relevant for expensive or limited-supply drugs, optimizing resource utilization and reducing healthcare costs.[25]

Ease of Dose Adjustment: Some polymer-based controlled release formulations allow for dose adjustment through simple modifications in formulation parameters, such as polymer composition, drug loading, or dosage form geometry. This flexibility enables healthcare providers to titrate doses according to individual patient responses, optimizing treatment outcomes while minimizing the risk of adverse effects.

Application of polymers in formulation of controlled release drug delivery systems

Polymers play a crucial role in the formulation of controlled release drug delivery systems across various routes of administration, offering numerous applications in pharmaceuticals and other industries. Here are some key applications of polymers in the formulation of controlled release drug delivery systems:

1. **Oral Drug Delivery**

- **Matrix Tablets:** Polymers such as hydroxypropyl methylcellulose (HPMC) or ethyl cellulose are commonly used to formulate matrix tablets for sustained release of drugs. These polymers provide controlled drug release by forming a gel matrix that retards drug diffusion.[26]
- **Coated Beads or Pellets:** Polymers like acrylic polymers (e.g., Eudragit) or cellulose derivatives are utilized to coat beads or pellets containing the drug. The coating controls drug release by diffusion through the polymer or by pH-dependent dissolution.[27]

2. **Transdermal Drug Delivery**

- **Polymer Matrix Patches:** Transdermal patches contain drug-loaded polymers (e.g., polyacrylates, silicones) that adhere to the skin and release drugs gradually over time. Polymers control drug permeation across the skin barrier, maintaining therapeutic plasma levels.[28]
- **Microneedle Arrays:** Polymers such as polyvinylpyrrolidone (PVP) or poly(lactic-co-glycolic acid) (PLGA) are used to fabricate microneedle arrays for transdermal delivery. These biodegradable polymers encapsulate drugs and facilitate controlled release upon insertion into the skin.[29]

3. **Injectable Drug Delivery**

- **Polymeric Microspheres:** Injectable microspheres composed of biodegradable polymers like PLGA or polylactic acid (PLA) encapsulate drugs for sustained release. These microspheres are administered via injection and gradually degrade, releasing the drug over an extended period.[30]
- **Hydrogels:** Injectable hydrogels based on polymers such as polyethylene glycol (PEG) or alginate can be loaded with drugs for localized delivery. These hydrogels form depots at the injection site and release drugs through diffusion or degradation.[31]

4. **Ophthalmic Drug Delivery**

- **Polymeric Inserts:** Ocular inserts made of polymers like HPMC or polyvinyl alcohol (PVA) are used for sustained drug release in the eye. These inserts adhere to the conjunctival sac and release drugs gradually, providing prolonged therapeutic effects.[32]
- **In Situ Gelling Systems:** Polymers such as methylcellulose or gellan gum can form in situ gels when instilled into the eye. These gels undergo gelation upon contact with ocular fluids, prolonging drug residence time and enhancing bioavailability.[33]

5. **Nasal Drug Delivery**

- **Mucoadhesive Polymers:** Nasal formulations utilize mucoadhesive polymers like chitosan or Carbopol to prolong drug residence time on the nasal mucosa. These polymers enhance drug absorption and provide sustained release, offering an alternative route for systemic drug delivery.[34]

6. **Implantable Drug Delivery**

- **Polymer Implants:** Biodegradable polymer implants, such as PLGA or polycaprolactone (PCL), are used for long-term drug delivery. These implants can be inserted subcutaneously or intramuscularly, releasing drugs continuously as the polymer degrades.[35]

7. **Inhalable Drug Delivery**

- **Polymer Nanoparticles:** Inhalable formulations utilize polymer nanoparticles, such as poly(lactic-co-glycolic acid) (PLGA) or chitosan, to encapsulate drugs for pulmonary delivery. These nanoparticles provide sustained release and target specific regions of the lungs for local or systemic effects.[36]

8. **Intravaginal Drug Delivery**

- **Polymeric Inserts and Rings:** Polymeric inserts or rings made of materials like silicone elastomers or ethylene vinyl acetate (EVA) are used for intravaginal drug delivery. These devices provide sustained release of drugs for the treatment of vaginal infections, contraception, or hormone replacement therapy.[37]

9. **Intraocular Drug Delivery**

- **Polymeric Implants:** Implantable devices made of biodegradable polymers such as PLGA or poly(ε-caprolactone) (PCL) are used for intraocular drug delivery. These implants can be surgically placed in the eye to release drugs over extended periods, providing treatment for conditions like macular degeneration or diabetic retinopathy.[38]

10. **Gastrointestinal Drug Delivery**

- **Enteric Coatings:** Polymers like methacrylic acid copolymers (Eudragit) are used to formulate enteric coatings for oral dosage forms. These coatings protect drugs from gastric degradation and release them in the intestine, allowing for site-specific delivery and improved bioavailability.[39]
- **Mucoadhesive Formulations:** Polymers with mucoadhesive properties, such as chitosan or sodium alginate, are employed to develop gastroretentive formulations. These formulations adhere to the gastric mucosa, prolonging gastric residence time and facilitating controlled drug release for localized or systemic effects.[40]

11. Rectal Drug Delivery

- **Suppositories:** Polymers like cocoa butter or polyethylene glycols (PEGs) are used to prepare rectal suppositories for controlled release drug delivery. These suppositories melt at body temperature, releasing drugs that are absorbed through the rectal mucosa for systemic or local effects.[41]

12. Intratumoral Drug Delivery

- **Polymer-Based Depots:** Injectable depots composed of biocompatible polymers, such as PLGA or polyethylene glycol (PEG), can be directly administered into tumors. These depots slowly release anticancer drugs locally, achieving high drug concentrations within the tumor while minimizing systemic toxicity.[42]

13. Oral Film Formulations

- **Polymer Films:** Thin oral films made of polymers like hydroxypropyl cellulose (HPC) or polyvinyl alcohol (PVA) can be loaded with drugs for controlled release. These films adhere to the oral mucosa and dissolve or disintegrate gradually, allowing for sustained drug release and improved bioavailability.[43]

14. Dermal and Topical Drug Delivery

- **Polymeric Nanoparticles:** Polymeric nanoparticles, such as PLGA or polymeric micelles, can encapsulate drugs for dermal or topical delivery. These nanoparticles penetrate the skin barrier and release drugs in a sustained manner, offering targeted therapy for skin conditions like acne, eczema, or psoriasis.[44]

CONCLUSION

Polymers are indispensable in the development of controlled release drug delivery systems due to their biocompatibility, biodegradability, versatility, and ability to regulate drug release. They enable the design of advanced formulations for oral, transdermal, injectable, ophthalmic, nasal, pulmonary, gastrointestinal, rectal, intravaginal, intraocular, dermal, and implantable drug delivery. By improving drug stability, bioavailability, therapeutic efficacy, and patient compliance while reducing dosing frequency and adverse effects, polymers have transformed modern pharmaceutical formulations. Continued advancements in polymer science, including smart and stimuli-responsive polymers, are expected to further enhance targeted, personalized, and efficient drug delivery systems, expanding their future clinical and industrial applications.

REFERENCES

1. M.F. Maitz,, Applications of synthetic polymers in clinical medicine, Biosurface and Biotribology, 2015; 1(3): 161-17
2. Dey, Joydeep, Comprehensive Classification and Structural Overview of Polymers: Origin, Structure, and Functional Characteristics, 2025.
3. Nokhodchi A, Raja S, Patel P, Asare-Addo K. The role of oral controlled release matrix tablets in drug delivery systems. Bioimpacts, 2012; 2(4): 175-87
4. Ciolacu DE, Nicu R, Ciolacu F. Cellulose-Based Hydrogels as Sustained Drug-Delivery Systems. Materials (Basel), 2020 Nov 21; 13(22): 5270
5. Makadia HK, Siegel SJ. Poly Lactic-co-Glycolic Acid (PLGA) as Biodegradable Controlled Drug Delivery Carrier. Polymers (Basel), 2011 Sep 1; 3(3): 1377-1397.

6. Dallaev R, Papež N, Allaham MM, Holcman V. Biodegradable Polymers: Properties, Applications, and Environmental Impact. Polymers (Basel), 2025 Jul 18; 17(14): 1981
7. Barakat Olamide Ishola, Khandoker Asiqur Rahaman, Shaikh Abdur Razzak, Md Mahamudul Hasan Rumon, Md Salman Shakil, Shihab Uddin, Advanced mechanisms of polymer-based drug delivery systems for clinical applications, RSC Pharmaceutics, 2026; 3(2): 331-360
8. Adepu S, Ramakrishna S. Controlled Drug Delivery Systems: Current Status and Future Directions. Molecules, 2021 Sep 29; 26(19): 5905
9. Fu Y, Kao WJ. Drug release kinetics and transport mechanisms of non-degradable and degradable polymeric delivery systems. Expert Opin Drug Deliv, 2010 Apr; 7(4): 429-44.
10. Boddupalli BM, Mohammed ZN, Nath RA, Banji D. Mucoadhesive drug delivery system: An overview. J Adv Pharm Technol Res, 2010 Oct; 1(4): 381-7.
11. Yoshida T, Lai TC, Kwon GS, Sako K. pH- and ion-sensitive polymers for drug delivery. Expert Opin Drug Deliv, 2013 Nov; 10(11): 1497-513.
12. Hamid Ali, Obaid Iqbal, Muhammad Sadiq, Yumeng Cheng, Xiao Yan, Basem Al Alwan, Atef El Jery, Hameed ur Rahman, Yongteng Qian, Asif Hayat, Dewu Yue, Zeeshan Ajmal, Novel advancements in synthesis, modulation, and potential applications of conjugated microporous polymer-based materials, Nano Materials Science, 2026; 8(1): 117-174
13. Umar AK, Butarbutar M, Sriwidodo S, Wathoni N. Film-Forming Sprays for Topical Drug Delivery. Drug Des Devel Ther, 2020 Jul 22; 14: 2909-2925.
14. Li X, Liu J, Qiu N. Cyclodextrin-Based Polymeric Drug Delivery Systems for Cancer Therapy. Polymers (Basel), 2023 Mar 11; 15(6): 1400.
15. Thang NH, Chien TB, Cuong DX. Polymer-Based Hydrogels Applied in Drug Delivery: An Overview. Gels, 2023 Jun 27; 9(7): 523
16. Abdulsalam L, Abubakar S, Permatasari I, Lawal AA, Uddin S, Ullah S, Ahmad I. Advanced Biocompatible and Biodegradable Polymers: A Review of Functionalization, Smart Systems, and Sustainable Applications. Polymers (Basel), 2025 Oct 30; 17(21): 2901
17. Fanse S, Bao Q, Zou Y, Wang Y, Burgess DJ. Impact of polymer crosslinking on release mechanisms from long-acting levonorgestrel intrauterine systems. Int J Pharm, 2022 Jan 25; 612: 121383.
18. Park K, Otte A, Sharifi F, Garner J, Skidmore S, Park H, Jhon YK, Qin B, Wang Y. Potential Roles of the Glass Transition Temperature of PLGA Microparticles in Drug Release Kinetics. Mol Pharm, 2021 Jan 4; 18(1): 18-32.
19. Patroklou G, Triantafyllopoulou E, Goula PE, Karali V, Chountoulesi M, Valsami G, Pispas S, Pippa N. pH-Responsive Hydrogels: Recent Advances in Pharmaceutical Applications. Polymers (Basel), 2025 May 23; 17(11): 1451.
20. Alkahtani ME, Elbadawi M, Chapman CAR, Green RA, Gaisford S, Orlu M, Basit AW. Electroactive Polymers for On-Demand Drug Release. Adv Healthc Mater, 2024 Jan; 13(3): e2301759.
21. Herczeg CK, Song J. Sterilization of Polymeric Implants: Challenges and Opportunities. ACS Appl Bio Mater, 2022 Nov 21; 5(11): 5077-5088.
22. Rahman M, Teimouri S, Roy PR, Raposo A, Alturki HA, Kasapis S. Strategies for Regulating the Release Kinetics of Bioactive Compounds from Biopolymeric Hydrogels. *Gels*, 2025; 11(12): 986.

23. Liechty WB, Kryscio DR, Slaughter BV, Peppas NA. Polymers for drug delivery systems. Annu Rev Chem Biomol Eng, 2010; 1: 149-73.
24. Zhang Y, Wu BM. Current Advances in Stimuli-Responsive Hydrogels as Smart Drug Delivery Carriers. Gels, 2023 Oct 22; 9(10): 838.
25. Fasola G, Aprile G, Marini L, Follador A, Mansutti M, Miscoria M. Drug waste minimization as an effective strategy of cost-containment in oncology. BMC Health Serv Res, 2014 Feb 7; 14: 57.
26. Hirun N, Kraisit P. Drug-Polymers Composite Matrix Tablets: Effect of Hydroxypropyl Methylcellulose (HPMC) K-Series on Porosity, Compatibility, and Release Behavior of the Tablet Containing a BCS Class I Drug. Polymers (Basel), 2022 Aug 19; 14(16): 3406.
27. Dos Santos J, da Silva GS, Velho MC, Beck RCR. Eudragit®: A Versatile Family of Polymers for Hot Melt Extrusion and 3D Printing Processes in Pharmaceutics. Pharmaceutics, 2021 Sep 8; 13(9): 1424.
28. Donato L, Bernardo P. Polymeric Membrane-Based Systems in Transdermal Drug Delivery. Polymers (Basel), 2026 Jan 30; 18(3): 376.
29. Chellathurai MS, Ling VWT, Palanirajan VK. Fabrication and Evaluation of Transdermal Microneedles for a Recombinant Human Keratinocyte Growth Factor. Turk J Pharm Sci., 2021 Feb 25; 18(1): 96-103.
30. Su Y, Zhang B, Sun R, Liu W, Zhu Q, Zhang X, Wang R, Chen C. PLGA-based biodegradable microspheres in drug delivery: recent advances in research and application. Drug Deliv, 2021 Dec; 28(1): 1397-1418.
31. Delgado-Pujol EJ, Martínez G, Casado-Jurado D, Vázquez J, León-Barberena J, Rodríguez-Lucena D, Torres Y, Alcudia A, Begines B. Hydrogels and Nanogels: Pioneering the Future of Advanced Drug Delivery Systems. Pharmaceutics, 2025 Feb 7; 17(2): 215.
32. Kumari A, Sharma PK, Garg VK, Garg G. Ocular inserts - Advancement in therapy of eye diseases. J Adv Pharm Technol Res, 2010 Jul; 1(3): 291-6.
33. Wu Y, Liu Y, Li X, Kebebe D, Zhang B, Ren J, Lu J, Li J, Du S, Liu Z. Research progress of in-situ gelling ophthalmic drug delivery system. Asian J Pharm Sci., 2019 Jan; 14(1): 1-15.
34. Porfiryeva, N. N., Moustafine, R. I., & Khutoryanskiy, V. V., Advances in mucoadhesive and mucus-penetrating materials, nano-formulations, and *in situ* gelling systems for nasal drug delivery. *Expert Opinion on Drug Delivery*, 2026; *23*(5): 797–822.
35. Omidian H, Wilson RL. PLGA Implants for Controlled Drug Delivery and Regenerative Medicine: Advances, Challenges, and Clinical Potential. Pharmaceuticals (Basel), 2025 Apr 27; 18(5): 631.
36. Francesca U, Ivana d'Angelo, Ciro C, Roberta d'Emma, Raffaella S, Brunella P, Maria A, Agnese M, Maria I, Fabiana Q, Dry powders based on PLGA nanoparticles for pulmonary delivery of antibiotics: Modulation of encapsulation efficiency, release rate and lung deposition pattern by hydrophilic polymers, Journal of Controlled Release, 2012; 157(1): 149-159
37. Rafiei F, Tabesh H, Farzad S, Farzaneh F, Rezaei M, Hosseinzade F, Mottaghy K. Development of Hormonal Intravaginal Rings: Technology and Challenges. Geburtshilfe Frauenheilkd, 2021 Jul; 81(7): 789-806.
38. García-Estrada P, García-Bon MA, López-Naranjo EJ, Basaldúa-Pérez DN, Santos A, Navarro-Partida J. Polymeric Implants for the Treatment of Intraocular Eye Diseases: Trends in Biodegradable and Non-Biodegradable Materials. Pharmaceutics, 2021 May 12; 13(5): 701.
39. Nikam A, Sahoo PR, Musale S, Pagar RR, Paiva-Santos AC, Giram PS. A Systematic Overview of Eudragit® Based Copolymer for Smart Healthcare. Pharmaceutics, 2023 Feb 9; 15(2): 587.

40. Amisha, Viresh Chandur, Chitosan In Gastroretentive Drug Delivery Systems: A Versatile Polymer For Prolonged Gastric Retention, Int. J. of Pharm. Sci., 2026; 4(6): 484-498
41. Ham AS, Buckheit RW Jr. Designing and developing suppository formulations for anti-HIV drug delivery. Ther Deliv, 2017 Aug; 8(9): 805-817.
42. Kim Y, Kwak J, Lim M, Lim SY, Chae S, Ha S-J, Won Y-W, Kim H-O, Lim KS. Advances in PCL, PLA, and PLGA-Based Technologies for Anticancer Drug Delivery. *Pharmaceutics*, 2025; 17(10): 1354.
43. Ajeet Kumar, Dr. K. Saravanan, Rapid Dissolving Film as Platform for Drug Delivery Systems: A Review, Int. J. of Pharm. Sci., 2025; 3(8): 2881-2912
44. Madawi EA, Al Jayoush AR, Rawas-Qalaji M, Thu HE, Khan S, Sohail M, Mahmood A, Hussain Z. Polymeric Nanoparticles as Tunable Nanocarriers for Targeted Delivery of Drugs to Skin Tissues for Treatment of Topical Skin Diseases. Pharmaceutics, 2023 Feb 15; 15(2): 657.